Early-stage drug study for advanced cancers that stopped responding
Part of Cancer clinical trials.
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old (either sex can join).
- Have advanced cancer that cannot be removed by surgery or has spread, and have tried standard treatment (or had no standard options, or could not tolerate it).
- Finish chemo/immunotherapy/targeted therapy/radiation (except local pain relief) at least 4 weeks before starting this study drug.
- Have at least one measurable tumor spot doctors can track on scans, and be well enough to do daily activities (ECOG 0 to 1).
- Blood tests and organ function must be adequate (for example, enough white blood cells, platelets, hemoglobin, kidney function, and liver function).
- If you can become pregnant or can father a child, you must use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a medicine called SGN1 given directly into a solid tumor. It’s for people with advanced cancers that have not responded to standard treatment (or don’t have good standard options) and aims to see if the injection is safe and may work.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.